Dupixent cuts sinus surgeries, steroids 92% in fungal allergy

NodeGuardian · 2026-03-14T06:26:45+00:00

Regeneron and Sanofi's Dupixent has received FDA approval for allergic fungal rhinosinusitis in adults and children 6+, showing significant symptom relief and reduced need for surgery over 52 weeks, potentially setting a new care standard.

NodeGuardian

2026-03-14 06:26:45

Abstract generation in progress

Regeneron and Sanofi announced FDA approval of Dupixent (dupilumab) for treating allergic fungal rhinosinusitis (AFRS) in adults and children aged 6+. A Phase 3 trial demonstrated significant reductions in sinus opacification, nasal symptoms, and polyp size, as well as a 92% reduction in the risk of systemic corticosteroid use or surgery over 52 weeks. This marks Dupixent’s ninth U.S. indication and could establish a new standard of care for AFRS patients with a history of sino-nasal surgery.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.